Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer

De Marchi, Tommaso LU ; Foekens, John A. ; Umar, Arzu and Martens, John W. M. (2016) In Drug Discovery Today 21(7). p.8-1181
Abstract

Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.

Please use this url to cite or link to this publication:
author
; ; and
publishing date
type
Contribution to journal
publication status
published
in
Drug Discovery Today
volume
21
issue
7
pages
8 pages
publisher
Elsevier
external identifiers
  • scopus:84969921763
  • pmid:27233379
ISSN
1878-5832
DOI
10.1016/j.drudis.2016.05.012
language
English
LU publication?
no
id
d7c8b01e-0eb3-49ac-a1e2-16ee7272dbc9
date added to LUP
2017-06-27 14:33:48
date last changed
2022-05-02 20:44:32
@article{d7c8b01e-0eb3-49ac-a1e2-16ee7272dbc9,
  abstract     = {{<p>Estrogen receptor (ER)-positive breast cancer represents the majority (∼70%) of all breast malignancies. In this subgroup of breast cancers, endocrine therapies are effective both in the adjuvant and recurrent settings, although resistance remains a major issue. Several high-throughput approaches have been used to elucidate mechanisms of resistance and to derive potential predictive markers or alternative therapies. In this review, we cover the state-of-the-art of endocrine-resistance biomarker discovery with regard to the latest technological developments, and discuss current opportunities and restrictions for their implementation into a clinical setting.</p>}},
  author       = {{De Marchi, Tommaso and Foekens, John A. and Umar, Arzu and Martens, John W. M.}},
  issn         = {{1878-5832}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{8--1181}},
  publisher    = {{Elsevier}},
  series       = {{Drug Discovery Today}},
  title        = {{Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer}},
  url          = {{http://dx.doi.org/10.1016/j.drudis.2016.05.012}},
  doi          = {{10.1016/j.drudis.2016.05.012}},
  volume       = {{21}},
  year         = {{2016}},
}